An example to support this argument is MGMT promoter methylation; while promoter methylation of MGMT has been reported as frequent in several cancer types, thus being correlated with cancer initiation and/or progression; Glioma patients harboring methylation of MGMT were found to be more responsive to alkylating agents than those without this epigenetic alteration [42], demonstrating its potential use in clinics. This evidence concerns the gene MGMT and cancer.